In a report released today, Alex Schwartz from Stifel Nicolaus reiterated a Buy rating on Puma Biotechnology (NYSEArca: PBYI), with a price target of $87. The company’s shares closed yesterday at $51.80.
According to TipRanks.com, Schwartz has currently no stars on a ranking scale of 0-5 stars, with an average return of -16.0% and a 21.4% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Verona Pharma Plc, vTv Therapeutics, and Clovis Oncology.
Currently, the analyst consensus on Puma Biotechnology is Moderate Buy and the average price target is $95.80, representing an 84.9% upside.
In a report issued on April 26, Credit Suisse also maintained a Buy rating on the stock with a $106 price target.
See today’s analyst top recommended stocks >>
Based on Puma Biotechnology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $24.3 million. In comparison, last year the company had a GAAP net loss of $72.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.
